Defining the course and prognosis of adults with acute lymphocytic leukemia in first salvage after induction failure or short first remission duration

Cancer

Volumn 116, Issue 24, 2010, Pages 5568-5574

  Kantarjian, Hagop M ^a   Thomas, Deborah ^a   Ravandi, Farhad ^a   Faderl, Stefan ^a   Jabbour, Elias ^a   Garcia Manero, Guillermo ^a   Pierce, Sherry ^a   Shan, Jianquin ^a   Cortes, Jorge ^a   O'Brien, Susan ^a  

^a UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

Author keywords

acute lymphocytic leukemia; complete response; prognosis; salvage therapy; survival

Indexed keywords

ALBUMIN; ASPARAGINASE; CLOFARABINE; CYCLOPHOSPHAMIDE; CYTARABINE; DEXAMETHASONE; DOXORUBICIN; LACTATE DEHYDROGENASE; METHOTREXATE; VINCRISTINE;

ACUTE LYMPHOCYTIC LEUKEMIA; ADOLESCENT; ADULT; AGE; AGED; ALLOGENEIC STEM CELL TRANSPLANTATION; CANCER RECURRENCE; DISEASE COURSE; HEMOGLOBIN BLOOD LEVEL; HUMAN; KARYOTYPE; LEUKEMIA REMISSION; MAJOR CLINICAL STUDY; PRIORITY JOURNAL; PROGNOSIS; REVIEW; SALVAGE THERAPY; SURVIVAL RATE; THROMBOCYTE COUNT; THROMBOCYTOPENIA;

ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; HUMANS; MIDDLE AGED; PRECURSOR CELL LYMPHOBLASTIC LEUKEMIA-LYMPHOMA; PROGNOSIS; RECURRENCE; REMISSION INDUCTION; SALVAGE THERAPY; TIME FACTORS;

EID: 78650083131     PISSN: 0008543X     EISSN: 10970142     Source Type: Journal    
DOI: 10.1002/cncr.25354     Document Type: Review

References (20)

1. Pui, CH Pui, Evans WE., Acute lymphoblastic leukemia. N Engl J Med. 1998; 339: 605-615.
2. Nachman JB, Sather HN, Sensel MG, et al. Augmented post-induction therapy for children with high-risk acute lymphoblastic leukemia and a slow response to initial therapy. N Engl J Med. 1998; 338: 1663-1671.
3. Kantarjian H, Thomas D, O'Brien S, et al. Long-term follow-up results of hyperfractionated cyclophosphamide, vincristine, doxorubicin, and dexamethasone (hyper-CVAD), a dose-intensive regimen, in adult acute lymphocytic leukemia. Cancer. 2004; 101: 2788-2801.
4. Faderl S, Jeha S, Kantarjian HM., The biology and therapy of adult acute lymphoblastic leukemia. Cancer. 2003; 98: 1337-1354.
5. Larson RA., Recent clinical trials in acute lymphocytic leukemia by the Cancer and Leukemia Group B. Hematol Oncol Clin North Am. 2000; 14: 1367-1379.
6. Durrant IJ, Richards SM, Prentice HG, Goldstone AH., The Medical Research Council trials in adult acute lymphocytic leukemia. Hematol Oncol Clin North Am. 2000; 14: 1327-1352.
7. Gokbuget N, Hoelzer D, Arnold R, et al. Treatment of adult ALL according to protocols of the German Multicenter Study Group for Adult ALL (GMALL). Hematol Oncol Clin North Am. 2000; 14: 1307-1325.
8. Thiebaut A, Vernant JP, Degos L, et al. Adult acute lymphocytic leukemia study testing chemotherapy and autologous and allogeneic transplantation. A follow-up report of the French protocol LALA 87. Hematol Oncol Clin North Am. 2000; 14: 1353-1366.
9. Jeha S, Kantarjian H., Clofarabine for the treatment of acute lymphoblastic leukemia. Expert Rev Anticancer Ther. 2007; 7: 113-118. (Pubitemid 46277276)
10. Jeha S, Gandhi V, Chan KW, et al. Clofarabine, a novel nucleoside analog, is active in pediatric patients with advanced leukemia. Blood. 2004; 103: 784-789.
11. DeAngelo DJ, Yu D, Johnson JL, et al. Nelarabine induces complete remissions in adults with relapsed or refractory T-lineage acute lymphoblastic leukemia or lymphoblastic lymphoma: Cancer and Leukemia Group B study 19801. Blood. 2007; 109: 5136-5142.
12. Ottmann OG, Druker BJ, Sawyers CL, et al. A phase 2 study of imatinib in patients with relapsed or refractory Philadelphia chromosome-positive acute lymphoid leukemias. Blood. 2002; 100: 1965-1971.
13. Ottmann O, Dombret H, Martinelli G, et al. Dasatinib induces rapid hematologic and cytogenetic responses in adult patients with Philadelphia chromosome positive acute lymphoblastic leukemia with resistance or intolerance to imatinib: interim results of a phase 2 study. Blood. 2007; 110: 2309-2315.
14. Fielding AK, Richards SM, Chopra R, et al. Medical Research Council of the United Kingdom Adult ALL Working Party; Eastern Cooperative Oncology Group. Outcome of 609 adults after relapse of acute lymphoblastic leukemia (ALL): an MRC UKALL12/ECOG 2993 study. Blood. 2007; 109: 944-950.
15. Tavernier E, Boiron JM, Huguet F, et al. GET-LALA Group; Swiss Group for Clinical Cancer Research SAKK; Australasian Leukaemia and Lymphoma Group. Outcome of treatment after first relapse in adults with acute lymphoblastic leukemia initially treated by the LALA-94 trial. Leukemia. 2007; 21: 1907-1914.
16. Garcia-Manero G, Thomas DA., Salvage therapy for refractory or relapsed acute lymphocytic leukemia. Hematol Oncol Clin North Am. 2001; 15: 163-205.
17. Thomas DA, Kantarjian H, Smith TL, et al. Primary refractory and relapsed adult acute lymphoblastic leukemia: characteristics, treatment results, and prognosis with salvage therapy. Cancer. 1999; 86: 1216-1230.
18. George SL, Ochs JJ, Mauer AM, Simone JV., The importance of an isolated central nervous system relapse in children with acute lymphoblastic leukemia. J Clin Oncol. 1985; 3: 776-781.
19. O'Brien S, Thomas D, Ravandi F, et al. Outcome of adults with acute lymphocytic leukemia after second salvage therapy. Cancer. 2008; 113: 3186-3191.
20. Cox DR,. Regression models and life tables. J Stat Soc (B). 1972; 34: 187-220.